嘉和生物今日盘中大涨5.37%，引起了市场的广泛关注。
消息面上，嘉和生物发布公告，拟根据股东于2025年6月26日授予的购回股份一般授权，在公开市场购回本公司股份。购回的股份将用于公司认为对其运营有利的用途。董事会相信，股份购回符合公司及其股东的整体利益。股份回购计划通常被视为公司对自身价值充满信心的表现，有助于减少流通股数量并可能提升每股收益，从而提振投资者情绪并推动股价上涨。
此次股份购回授权为公司在公开市场操作提供了灵活性，公司表示将根据市场情况适时进行购回，并后续将购回的股份注销、保留于库存、出售或转让。这一举措进一步强化了公司资本管理的策略，并可能对股价形成支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.